Curis Inc Asset Resilience Ratio
Curis Inc asset resilience ratio. Curis Inc (CRIS) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CRIS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Curis Inc (1999–2024)
Asset resilience ratio of Curis Inc from 1999 to 2024. This chart shows how Curis Inc's Asset Resilience Ratio has changed over time. Read CRIS current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Curis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CRIS total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Curis Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Curis Inc Industry Peers by Asset Resilience Ratio
Compare Curis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Curis Inc Asset Resilience Ratio by Year (1999–2024)
Curis Inc asset resilience ratio by year from 1999 to 2024. The table below shows the annual Asset Resilience Ratio data for Curis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $41.27 Million | -- |
| 2023-12-31 | 38.37% | $29.65 Million | $77.28 Million | -22.23pp |
| 2022-12-31 | 60.60% | $65.97 Million | $108.85 Million | +13.86pp |
| 2021-12-31 | 46.75% | $75.87 Million | $162.30 Million | +27.72pp |
| 2020-12-31 | 19.03% | $38.88 Million | $204.36 Million | +4.46pp |
| 2019-12-31 | 14.56% | $5.11 Million | $35.11 Million | +12.87pp |
| 2018-12-31 | 1.70% | $634.00K | $37.37 Million | -28.04pp |
| 2017-12-31 | 29.74% | $21.94 Million | $73.80 Million | -2.21pp |
| 2016-12-31 | 31.94% | $18.45 Million | $57.75 Million | -19.76pp |
| 2015-12-31 | 51.70% | $49.10 Million | $94.97 Million | -15.38pp |
| 2014-12-31 | 67.08% | $42.00 Million | $62.61 Million | +6.79pp |
| 2013-12-31 | 60.29% | $48.59 Million | $80.59 Million | -0.86pp |
| 2012-12-31 | 61.15% | $42.79 Million | $69.98 Million | +60.66pp |
| 2011-12-31 | 0.49% | $235.91K | $48.18 Million | -64.22pp |
| 2010-12-31 | 64.71% | $32.77 Million | $50.65 Million | +14.91pp |
| 2009-12-31 | 49.79% | $17.98 Million | $36.10 Million | +3.04pp |
| 2008-12-31 | 46.76% | $18.69 Million | $39.98 Million | +2.04pp |
| 2007-12-31 | 44.71% | $24.06 Million | $53.82 Million | +10.61pp |
| 2006-12-31 | 34.11% | $17.83 Million | $52.27 Million | -1.84pp |
| 2005-12-31 | 35.95% | $21.90 Million | $60.91 Million | -3.72pp |
| 2004-12-31 | 39.67% | $26.83 Million | $67.63 Million | +26.37pp |
| 2003-12-31 | 13.30% | $7.41 Million | $55.74 Million | -2.16pp |
| 2002-12-31 | 15.46% | $9.65 Million | $62.44 Million | +6.36pp |
| 2001-12-31 | 9.10% | $13.17 Million | $144.76 Million | -3.30pp |
| 2000-12-31 | 12.40% | $22.65 Million | $182.68 Million | -52.04pp |
| 1999-12-31 | 64.44% | $18.62 Million | $28.89 Million | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. … Read more